Literature DB >> 1922820

Coexistence of Lambert-Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment.

A M Blumenfeld1, L D Recht, D A Chad, U DeGirolami, T Griffin, K A Jaeckle.   

Abstract

A 61-year-old woman presented with two paraneoplastic neurologic disorders--Lambert-Eaton myasthenic syndrome (LEMS) and subacute cerebellar degeneration (SCD)--that antedated the diagnosis of small-cell carcinoma of the lung by 15 months. Plasmapheresis initiated before the identification of the tumor had a beneficial effect on LEMS but did not affect the SCD. Chemotherapy administered for treatment of the primary tumor was also associated with improvement of LEMS but, like plasmapheresis, had no effect on SCD. While the pathogenesis of both LEMS and SCD is thought to be mediated predominantly by humoral immune factors, a differential therapeutic response indicates that mechanisms of tissue damage or susceptibility to tissue injury, or both, differ in these two disorders.

Entities:  

Mesh:

Year:  1991        PMID: 1922820     DOI: 10.1212/wnl.41.10.1682

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders.

Authors:  Josep Dalmau; Luis Bataller
Journal:  Hematol Oncol Clin North Am       Date:  2006-12       Impact factor: 3.722

2.  Multiple paraneoplastic syndromes in a patient with antibodies to neuronal nucleoproteins (anti-Hu).

Authors:  F Heidenreich; R Schober; U Brinck; H P Hartung
Journal:  J Neurol       Date:  1995-03       Impact factor: 4.849

3.  Subacute cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with antibodies to voltage-gated calcium channels: differential effect of immunosuppressive therapy on central and peripheral defects.

Authors:  J M Goldstein; S G Waxman; T L Vollmer; B Lang; I Johnston; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 4.  Neurological paraneoplastic syndromes.

Authors:  U Nath; R Grant
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

5.  Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies.

Authors:  Michael Winklehner; Jan Bauer; Verena Endmayr; Carmen Schwaiger; Gerda Ricken; Masakatsu Motomura; Shunsuke Yoshimura; Hiroshi Shintaku; Kinya Ishikawa; Yukio Tsuura; Takahiro Iizuka; Takanori Yokota; Takashi Irioka; Romana Höftberger
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-07-07

Review 6.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain.

Authors:  R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  Lambert-Eaton myasthenic syndrome as a cause of persistent neuromuscular weakness after a mediastinoscopic biopsy -A case report-.

Authors:  Cheol Jin Lee; Se Hun Lim; Chee Mahn Shin; Young Jae Kim; Young Kyun Choe; Soon Ho Cheong; Kun Moo Lee; Jeong Han Lee; Young Hwan Kim; Kwang Rae Cho; Sang Eun Lee; Jong Suk Bae
Journal:  Korean J Anesthesiol       Date:  2010-07-21

8.  Paraneoplastic cerebellar degeneration and limbic encephalitis in a patient with adenocarcinoma of the colon.

Authors:  T Tsukamoto; R Mochizuki; H Mochizuki; M Noguchi; H Kayama; M Hiwatashi; T Yamamoto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

9.  Voltage-gated calcium channel autoimmune cerebellar degeneration: Case and study of cytotoxicity.

Authors:  Marilyn McKasson; Stacey L Clardy; Susan A Clawson; Kenneth E Hill; Blair Wood; Noel Carlson; Mark Bromberg; John E Greenlee
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-03-31

10.  Treatment of paraneoplastic cerebellar degeneration.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.